ProfileGDS5678 / 1432948_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 33% 32% 32% 31% 32% 34% 32% 32% 31% 32% 32% 31% 32% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7892533
GSM967853U87-EV human glioblastoma xenograft - Control 22.7308132
GSM967854U87-EV human glioblastoma xenograft - Control 32.7321832
GSM967855U87-EV human glioblastoma xenograft - Control 42.6528131
GSM967856U87-EV human glioblastoma xenograft - Control 52.679432
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8435534
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7783532
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7048532
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6802931
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7161932
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7171732
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6781431
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7287832
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7219832